close auction, page-11

Port has given generally excellent posts/coverage regarding pros and cons of Biota.

Maybe the point Port is making is that the BTA management's settlement has allowed for GSK and BTA to have a more positive relationship in the current situation - IMO, that should have a positive effect on the sp of BTA. If GSK priorities/bias are compromised by selling vaccines at the same time as Relenza, I think it would be even more compromised if they were in court with BTA - that is, I think GSK would not promote Relenza as much as they currently are.

In that sense maybe it is good that BTA have settled with GSK.

Of course, in hindsight they should have settled for the $100 M + legal costs.